Quarterly ResultMay 7, 2026, 04:29 PM
BioLife Solutions Q1 Net Income $1.19M; EPS $0.02
AI Summary
BioLife Solutions reported a net income of $1.19 million for Q1 2026, a significant improvement from a net loss of $0.45 million in Q1 2025. Revenue increased to $27.5 million from $22.05 million year-over-year. The company also completed the divestment of its SAVSU business in October 2025, recognizing a $10.32 million gain, and acquired the remaining 90% of PanTHERA CryoSolutions in April 2025, expensing $15.5 million for IPR&D.
Key Highlights
- Net income for Q1 2026 was $1.19 million, up from a net loss of $0.45 million in Q1 2025.
- Basic net income per share was $0.02 in Q1 2026, compared to a loss of $0.01 in Q1 2025.
- Revenue for Q1 2026 increased to $27.5 million from $22.05 million in Q1 2025.
- Operating income improved to $27,000 in Q1 2026 from an operating loss of $499,000 in Q1 2025.
- Recognized a $10.32 million net gain on the disposal of the SAVSU business in Q4 2025.
- Expensed $15.5 million for in-process R&D from the PanTHERA acquisition in Q2 2025.
- Net cash used in operating activities was $0.49 million in Q1 2026, compared to $1.73 million provided in Q1 2025.
- Total cash, cash equivalents, and available-for-sale securities were $111.5 million as of March 31, 2026.
Price Impact
More from BLFS